Research spans clinical outcomes and biomarker‑informed diagnostics in lymphoma and myeloma, evaluating CAR‑T and bispecific strategies. Standardizes cachexia assessment and functional metrics, linking muscle biology with rehabilitation‑relevant endpoints to inform treatment planning and survivorship.